Seaport Therapeutics

Showing 2 posts of 2 posts found.

mental-health-3332122_960_720

Seaport Therapeutics doses first patient in trial of GlyphAllo for depression

July 25, 2025
Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions

Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …

David Wheadon appointed to board of directors at Seaport Therapeutics

August 14, 2024
Corporate, Seaport Therapeutics, appointment

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

The Gateway to Local Adoption Series

Latest content